<DOC>
	<DOCNO>NCT01069809</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness AGS-004 , immune therapy , HIV-infected individual . Safety effectiveness test individual take antiretroviral therapy ( ART ) medication interrupt ART medication .</brief_summary>
	<brief_title>Safety Efficacy Study AGS-004 During Analytical Treatment Interruption</brief_title>
	<detailed_description>The purpose study determine safety effectiveness AGS-004 , immune therapy , HIV-infected individual . Safety effectiveness test individual take antiretroviral therapy ( ART ) medication interrupt ART medication</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Males females ≥ 18 60 year age . 2 . HIV infection . 3 . Stable ART regimen ≥ 3 month prior Screening . 4 . HIV VL level ≤ 400 copies/mL ≥ 2 month prior Screening . 5 . HIV VL level ≤ 50 copies/mL Screening . 6 . CD4+ T cell count ≥ 450 cells/mm3 Screening . 7 . PreART nadir CD4+ T cell count ≥ 200 cells/mm³ . 8 . Availability adequate sample frozen plasma recently collect ( 90 day preferably within 30 day ) start ART . 9 . Laboratory value within predefined limit Screening Eligibility . 10 . Negative serum pregnancy test Screening Eligibility female reproductive potential , agreement subject use reliable form contraception study 12 week last dose study drug . 11 . Able willing give adequate write informed consent , communicate effectively study personnel , willing compliant protocol requirement . 1 . HIV2 antibody positive Screening Visit . 2 . Positive hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibody ( positive HCV antibody , HCV RNA must negative ) . 3 . Untreated syphilis infection ( positive rapid plasma reagin [ RPR ] ) . 4 . Changes ART regimen due virologic breakthrough . 5 . History lymph node irradiation dissection . 6 . Prior use HIV immunotherapy vaccine within 9 month prior Screening . 7 . Prior participation AGS004 clinical study . 8 . Treatment interruption ART &gt; 1 month since start ART preART plasma sample drawn . 9 . Any acute infection medical illness within 14 day prior Screening throughout pretreatment evaluation phase ( Step 1 ) . 10 . Initiation ART acute HIV infection stage , date infection know ( acute infection define &lt; 6 month date HIV infection ART start date ) . 11 . Pregnancy breastfeed . 12 . Receipt immune modulators suppressor within 30 day prior Screening throughout pretreatment evaluation phase ( Step 1 ) . 13 . Evidence hepatic decompensation cirrhotic subject : history ascites , hepatic encephalopathy , bleed esophageal varix , screen laboratory result follow : International Normalized Ratio ( INR ) ≥ 1.5 X upper limit normal ( ULN ) ; Serum albumin &lt; 3.3 g/dL ; Serum total bilirubin &gt; 1.8 X ULN , unless history Gilbert 's disease deem related treatment atazanavir . 14 . History clinical evidence significant unstable cardiac disease ( e.g. , angina , congestive heart failure , recent myocardial infarction , significant arrhythmia ) clinically significant electrocardiogram ( ECG ) abnormality . 15 . History moderate severe renal impairment ( i.e. , persistent history creatinine clearance &lt; 50 mL/min ) renal disorder deem clinically significant investigator . 16 . Prior history acquire immunodeficiency syndrome ( AIDS ) define condition . 17 . History evidence severe illness , malignancy , immunodeficiency HIV , condition would make subject unsuitable study opinion investigator . 18 . Known allergy sensitivity component investigational immunotherapy . 19 . Active drug alcohol use dependence would interfere adherence study requirement opinion investigator . 20 . Use systemic corticosteroid use topical steroid total area exceed 15 cm² within 30 day prior Screening . 21 . Any investigational antiretroviral agent use CCR5 inhibitor Screening . 22 . Active autoimmune disease condition . 23 . Participation another investigational clinical study within previous 30 day use investigational agent . 24 . Body weight less 30 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>